Companion Medical’s InPen Approved in Peds; BrightInsight Secures $40M Series B Funding

Two diabetes-related items have been observed: Companion Medical announced FDA approval of its InPen for use in all ages and BrightInsight announced a Series B funding round of $40M. Below, FENIX provides thoughts on the expanded indication for InPen and BrightInsight’s funding.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.